Microbiotica To Present At Leading Microbiome Summit

Published: Sep 18, 2017

Cambridge, UK, Monday 18th September – Microbiotica, a leading player in microbiome-based therapeutics, today announces that CEO, Dr Mike Romanos, will present at the Annual Microbiome Summit: Translating into Diagnostics and BioTherapeutics, 21-22 September, in Vienna, Austria.

Dr Romanos’ talk “The Discovery of Novel Bacterial Therapeutics and Biomarkers Based on Deep Microbiome Analysis” will take place on 22nd September at 2.30 pm. His talk will focus on the importance of identifying gut bacteria with patient phenotype, the role of gut bacteria in immunotherapy response, and how these factors are key to the discovery of bacterial therapeutics.

The Summit brings together companies at the cutting-edge of microbiome research and provides a platform to engage and discuss current challenges, best practice and the future of microbiome in precision medicine.

Microbiotica, spun-out of the Wellcome Trust Sanger Institute in 2016, was formed around ground-breaking research led by Dr Trevor Lawley and is focused on microbiome biology, and its use in medicine, covering both novel bacterial therapeutics and patient diagnostics.

-ENDS-

Notes to Editors

About Microbiotica

• Microbiotica was established in 2016 to develop and commercialise ground-breaking research into the role of the human microbiome in health and disease and its application to medicine conducted in the Host-Microbiotica Interactions Laboratory (“HMIL”) at the Sanger Institute.

• Microbiotica’s founders are Mike Romanos, Trevor Lawley and Gordon Dougan, FRS.

• CIC and IP Group are co-investors in Microbiotica, with a £4m contribution from each party to provide total initial funding of £8m.

• Microbiotica is based at the Wellcome Genome Campus in Cambridge, UK, with offices in the Biodata Innovation Centre and laboratories in the Sanger Institute.

• www.microbiotica.com

About the Microbiomev

Recognition of the importance of the microbiome, the body’s trillions of resident bacteria, represents a paradigm-shift in our understanding of its impact on human health and disease. This creates major opportunities in the diagnosis and treatment of a wide range of disease including enteric infections, autoimmune disorders, metabolic disorders, cancer and neurological disease.

Microbiotica
Rowena Gardner
rgardner@microbiotica.com
+44 1223 786063 / +44 7801 480569

Instinctif Partners (for media enquiries):
Sue Charles/Gemma Harris
microbiotica@instinctif.com
+44 20 7866 7860

Back to news